CS-1003

Summary

Cs-1003 (CHEMBL4594536) is a phase-3 clinical-stage unknown; indicated across 4 conditions including hepatocellular carcinoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594536
Name	CS-1003
Type	Unknown
Max phase	3

Also known as: Antibody cs1003, CS 1003, Cs-1003, CS-1003, Cs1003, CS1003, Nofazinlimab, Recombinant pd-1 mab cs1003

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
neoplasm	1	MONDO:0005070	EFO:0000616
lymphoma	1	MONDO:0005062	EFO:0000574

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04194775	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
NCT03475251	PHASE1	COMPLETED	A Study of CS1003 in Subjects With Advanced Solid Tumors
NCT03523819	PHASE1	COMPLETED	A Study of CS1002 in Subjects with Advanced Solid Tumors

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).